The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
The Therapeutic Goods Administration (TGA) issued 4 infringement notices totalling $75,120 to Queensland based pharmacy Summit Pharmacy Pty Ltd, for the alleged unlawful manufacturing of medicinal cannabis products. Summit Pharmacy Pty Ltd paid all 4 infringement notices in February 2025.
The infringement notices followed an inspection by the TGA and Queensland Health in August 2024 that found the pharmacy was manufacturing medicinal cannabis oils in bulk amounts, in alleged contravention of the Therapeutic Goods Act 1989 (the Act).
The Act prohibits the manufacturing of therapeutic goods unless the goods are entered in the Australian Register of Therapeutic Goods or subject to an exemption, approval or authority.
Individuals and businesses, including pharmacists and pharmacies, must ensure that they comply with all regulatory requirements prior to the manufacture and supply of compounded medicinal cannabis products.
The TGA will take enforcement action where serious non-compliance with the Act is identified in accordance with our regulatory compliance framework. This may include issuing infringement notices, directions and prevention notices, or civil or criminal proceedings.
If you suspect non-compliance in relation to therapeutic goods, or their advertising, you can report it to the TGA at any time.
Contact for members of the media:
- Email: news@health.gov.au
- Phone: 02 6289 7400